polynovo signed contract sale aod9604 lateral pharma Exclusives Archive AOD-9604 (10mg vials) - Peptide

Both manufactured via SPPS with synthetic amino acids no animal-derived materials

The announcement was widely interpreted as a signal that the FDA under the new administration would take a more permissive stance toward peptide compounding than the 2023 Pharmacy Compounding Advisory Committee position, which had placed BPC-157 firmly in Category 2 (substances the FDA had concerns about for compounding use)

A Certificate of Analysis is available on request

It is typically administered subcutaneously at 50100 mg daily in timed cycles, with noticeable energy and body-composition changes emerging within 38 weeks and side effects generally mild and transient